Drug intelligence / Profile preview

SFA-002D

Development stage: Unknown
Lead developer: SFA Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**SFA-002D** is an investigational oral therapeutic developed by SFA Therapeutics for psoriasis. SFA Therapeutics describes the program as intended to reset immune activity and as a proof of concept for potential application in autoimmune diseases. Public company communications in August 2026 indicated that SFA-002D was being prepared for Phase 2 development in psoriasis; no approved indication, International Nonproprietary Name, marketed brand name, or molecular structure was identified in the reviewed public sources.

Targets

HDAC (HDAC family)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on SFA-002D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFA-002D.

Explore the full profile